TN2013000427A1 - Modified acid alpha glucosidase with accelerated processing - Google Patents

Modified acid alpha glucosidase with accelerated processing

Info

Publication number
TN2013000427A1
TN2013000427A1 TNP2013000427A TN2013000427A TN2013000427A1 TN 2013000427 A1 TN2013000427 A1 TN 2013000427A1 TN P2013000427 A TNP2013000427 A TN P2013000427A TN 2013000427 A TN2013000427 A TN 2013000427A TN 2013000427 A1 TN2013000427 A1 TN 2013000427A1
Authority
TN
Tunisia
Prior art keywords
acid alpha
accelerated processing
alpha glucosidase
modified acid
glucosidase
Prior art date
Application number
TNP2013000427A
Other languages
English (en)
French (fr)
Inventor
William M Canfield
Rodney J Moreland
Mariko Kudo
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000427(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of TN2013000427A1 publication Critical patent/TN2013000427A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TNP2013000427A 2011-04-22 2013-10-18 Modified acid alpha glucosidase with accelerated processing TN2013000427A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478336P 2011-04-22 2011-04-22
PCT/US2012/034479 WO2012145644A1 (en) 2011-04-22 2012-04-20 Modified acid alpha glucosidase with accelerated processing

Publications (1)

Publication Number Publication Date
TN2013000427A1 true TN2013000427A1 (en) 2015-03-30

Family

ID=46000406

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000427A TN2013000427A1 (en) 2011-04-22 2013-10-18 Modified acid alpha glucosidase with accelerated processing

Country Status (24)

Country Link
US (1) US20140186326A1 (enExample)
EP (1) EP2699676A1 (enExample)
JP (2) JP2014513952A (enExample)
KR (1) KR20140037082A (enExample)
CN (1) CN103797115A (enExample)
AU (1) AU2012245280A1 (enExample)
BR (1) BR112013026976A2 (enExample)
CA (1) CA2833371A1 (enExample)
CL (1) CL2013003010A1 (enExample)
CO (1) CO6811810A2 (enExample)
CR (1) CR20130555A (enExample)
EC (1) ECSP13013036A (enExample)
GT (1) GT201300252A (enExample)
IL (1) IL228871A0 (enExample)
MA (1) MA35125B1 (enExample)
MX (1) MX2013012345A (enExample)
NI (1) NI201300110A (enExample)
PE (1) PE20140617A1 (enExample)
PH (1) PH12013502149A1 (enExample)
RU (1) RU2013151875A (enExample)
SG (2) SG10201605874TA (enExample)
TN (1) TN2013000427A1 (enExample)
WO (1) WO2012145644A1 (enExample)
ZA (1) ZA201307696B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2901978A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
SI4273241T1 (sl) 2014-09-30 2025-03-31 Amicus Therapeutics, Inc. Zelo močna kislinska alfa-glukozidaza z okrepljenimi ogljikovimi hidrati
CN108474788A (zh) * 2015-11-06 2018-08-31 生物马林药物股份有限公司 用于检测中和溶酶体酶的摄取的抗体或其它因子的基于细胞的测定
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
CA3019128A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
NZ786723A (en) 2016-03-30 2025-07-25 Amicus Therapeutics Inc Method for selection of high m6p recombinant proteins
BR112019004785A2 (pt) 2016-09-12 2019-06-04 Genethon variantes de alfa-glicosidase ácida e usos das mesmas
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
DK3624831T5 (da) 2017-05-15 2024-09-02 Amicus Therapeutics Inc Rekombinant human sur alfa-glucosidase
MA50546A (fr) 2017-06-07 2020-09-16 Regeneron Pharma Compositions et méthodes pour l'internalisation d'enzymes
KR101942093B1 (ko) * 2018-01-05 2019-01-24 인하대학교 산학협력단 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물
AU2019218892B2 (en) 2018-02-07 2025-08-14 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
AU2019269685B2 (en) 2018-05-17 2025-12-04 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
US20220331408A1 (en) 2019-07-09 2022-10-20 Genethon Treatment of glycogen storage disease (gsd)
CN116096895A (zh) * 2019-11-19 2023-05-09 阿斯克肋匹奥生物制药公司 用于治疗庞贝氏病和溶酶体紊乱的包含肝特异性启动子的治疗性腺相关病毒

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
AU734290B2 (en) 1997-10-29 2001-06-07 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
PT2020438T (pt) 1998-12-07 2018-07-13 Genzyme Corp Tratamento da doença de pompe
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
ATE554082T1 (de) 2001-07-16 2012-05-15 Genzyme Corp N-acetylsphingosin glukosyltransferase inhibitor
AU2002348261A1 (en) 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20040248262A1 (en) * 2003-01-22 2004-12-09 Koeberl Dwight D. Constructs for expressing lysomal polypeptides
US20100196345A1 (en) 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
SI2332972T1 (en) 2003-06-24 2018-05-31 Genzyme Corporation New beta-actin and rpS21 promoters and their use
US20050244400A1 (en) * 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
EP2099523A2 (en) * 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Methods for treating pompe disease
PT2465542E (pt) 2008-12-16 2015-04-16 Genzyme Corp Conjugados oligossacárido-proteína
WO2010096369A1 (en) * 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof

Also Published As

Publication number Publication date
MA35125B1 (fr) 2014-05-02
KR20140037082A (ko) 2014-03-26
RU2013151875A (ru) 2015-05-27
SG10201605874TA (en) 2016-09-29
CL2013003010A1 (es) 2014-03-07
CN103797115A (zh) 2014-05-14
CO6811810A2 (es) 2013-12-16
EP2699676A1 (en) 2014-02-26
GT201300252A (es) 2015-02-09
US20140186326A1 (en) 2014-07-03
PE20140617A1 (es) 2014-05-28
ECSP13013036A (es) 2015-04-30
MX2013012345A (es) 2015-05-07
CA2833371A1 (en) 2012-10-26
JP2017035091A (ja) 2017-02-16
IL228871A0 (en) 2013-12-31
WO2012145644A1 (en) 2012-10-26
NI201300110A (es) 2014-02-28
AU2012245280A1 (en) 2013-11-07
CR20130555A (es) 2013-12-09
BR112013026976A2 (pt) 2019-09-24
SG194486A1 (en) 2013-12-30
JP2014513952A (ja) 2014-06-19
ZA201307696B (en) 2014-07-30
PH12013502149A1 (en) 2019-09-02

Similar Documents

Publication Publication Date Title
TN2013000427A1 (en) Modified acid alpha glucosidase with accelerated processing
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
IN2012DN03824A (enExample)
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
PH12014502698B1 (en) Improved antagonist antibodies against gdf-8 and uses therefor
PH12014500767A1 (en) Compositions for the treatment of dry eye
IN2014DN09782A (enExample)
MX2013001580A (es) Composiciones que comprenden un polipeptido que tiene actividad de incremento celulolitico y un licor, y usos de las mismas.
NZ603901A (en) Vectors and sequences for the treatment of diseases
IN2012DN02645A (enExample)
PH12012501680A1 (en) Compositions and methods for the diagnosis and treatment of tumor
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
PH12013501894A1 (en) Human tissue factor antibody and uses thereof
EA201891507A1 (ru) Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе
WO2012047951A3 (en) Human lung stem cells and uses thereof
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
MX2012001306A (es) Inhibicion de matastasis de tumor.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2013008530A (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
PH12012501963A1 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX2015015519A (es) Regulador de papalisina.